WO2004016220A3 - Voies d'apicomplexan, inhibiteurs et administration de medicaments - Google Patents

Voies d'apicomplexan, inhibiteurs et administration de medicaments Download PDF

Info

Publication number
WO2004016220A3
WO2004016220A3 PCT/US2003/025571 US0325571W WO2004016220A3 WO 2004016220 A3 WO2004016220 A3 WO 2004016220A3 US 0325571 W US0325571 W US 0325571W WO 2004016220 A3 WO2004016220 A3 WO 2004016220A3
Authority
WO
WIPO (PCT)
Prior art keywords
apicomplexan
parvum
gene
aox
demonstrates
Prior art date
Application number
PCT/US2003/025571
Other languages
English (en)
Other versions
WO2004016220A2 (fr
Inventor
Rima L Mcleod
Ernest J Mui
Benjamin U Samuel
Douglas G Mack
Michael J Kirisits
Paul Wender
Jonathan Rothbard
Brian Hearn
Craig W Roberts
David W Rice
Stephen P Muench
Sean Prigge
Samantha A Campbell
John R Coggins
Fiona Roberts
Fiona L Henriquez
Wilbur K Milhous
Dennis E Kyle
Original Assignee
Rima L Mcleod
Ernest J Mui
Benjamin U Samuel
Douglas G Mack
Michael J Kirisits
Paul Wender
Jonathan Rothbard
Brian Hearn
Craig W Roberts
David W Rice
Stephen P Muench
Sean Prigge
Samantha A Campbell
John R Coggins
Fiona Roberts
Fiona L Henriquez
Wilbur K Milhous
Dennis E Kyle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rima L Mcleod, Ernest J Mui, Benjamin U Samuel, Douglas G Mack, Michael J Kirisits, Paul Wender, Jonathan Rothbard, Brian Hearn, Craig W Roberts, David W Rice, Stephen P Muench, Sean Prigge, Samantha A Campbell, John R Coggins, Fiona Roberts, Fiona L Henriquez, Wilbur K Milhous, Dennis E Kyle filed Critical Rima L Mcleod
Priority to AU2003259848A priority Critical patent/AU2003259848A1/en
Priority to EP03788516A priority patent/EP1534837A4/fr
Priority to CA002535760A priority patent/CA2535760A1/fr
Publication of WO2004016220A2 publication Critical patent/WO2004016220A2/fr
Publication of WO2004016220A3 publication Critical patent/WO2004016220A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un gène Fab I d'apicomplexan et le gène pour la DAHP synthase dans Toxoplasma gondii et leurs enzymes codées constituent des moyens pour développer de façon rationnelle de nouvelles compositions inhibitrices, utiles dans la prévention et le traitement des maladies liées à l'apicomplexan. On peut, par exemple, utiliser le triclosan en tant que composé principal. L'administration d'inhibiteurs aux micro-organismes au moyen de polymères d'acides aminés courts est un nouveau procédé de traitement des infections actives et une nouvelle méthode pour acheminer des anti-microbiens jusqu'aux parasites latents enkystés. La voie de shikimate est cruciale pour la survie des parasites d'apicomplexan Plasmodium falciparum, Toxoplasma gondii et Cryptosporidium parvum. En raison de son absence chez les mammaliens, elle représente une cible thérapeutique intéressante. L'invention concerne aussi des gènes codant les eznymes de la voie de shikimate T. gondii. Des séquences supposées d'AOX ont été identifiées et séquencées à partir des souches de type 1 et de type 2 de C. parvum. Le gène code pour un polypeptide de 336 acides aminés et comprend une séquence de transit N-terminale similaire à celle présente dans des protéines ciblées sur les mitochondries d'autres espèces. L'oxydase alternative (AOX) est une autre cible des nouveaux agents anti-microbiens pour C. parvum.
PCT/US2003/025571 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments WO2004016220A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003259848A AU2003259848A1 (en) 2002-08-15 2003-08-14 Apicomplexan pathways, inhibitors, and drug delivery
EP03788516A EP1534837A4 (fr) 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments
CA002535760A CA2535760A1 (fr) 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US40403302P 2002-08-15 2002-08-15
US60/404,033 2002-08-15
US43820503P 2003-01-06 2003-01-06
US60/438,205 2003-01-06
US46343203P 2003-04-16 2003-04-16
US60/463,432 2003-04-16
US47288703P 2003-05-23 2003-05-23
US60/472,887 2003-05-23

Publications (2)

Publication Number Publication Date
WO2004016220A2 WO2004016220A2 (fr) 2004-02-26
WO2004016220A3 true WO2004016220A3 (fr) 2005-02-24

Family

ID=31892261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025571 WO2004016220A2 (fr) 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments

Country Status (4)

Country Link
EP (1) EP1534837A4 (fr)
AU (1) AU2003259848A1 (fr)
CA (1) CA2535760A1 (fr)
WO (1) WO2004016220A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
WO2006095837A1 (fr) * 2005-03-09 2006-09-14 National University Corporation Hokkaido University Structure lipidique membranaire capable de distribuer une substance cible a la mitochondrie
CN118750592A (zh) * 2024-09-06 2024-10-11 华南农业大学 一种缺失TgAROM基因的弓形虫减毒活疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403337B1 (en) * 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052614A2 (fr) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition et procede permettant d'ameliorer les transports a travers des membranes biologiques
WO2001027262A1 (fr) * 1999-10-13 2001-04-19 Pantheco A/S Selection de genes utilisant des sequences de pna
AU3773102A (en) * 2000-12-21 2002-07-01 Rima Mcleod Fab i and inhibition of apicomplexan parasites

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403337B1 (en) * 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1534837A4 *

Also Published As

Publication number Publication date
AU2003259848A1 (en) 2004-03-03
EP1534837A4 (fr) 2006-09-20
WO2004016220A2 (fr) 2004-02-26
EP1534837A2 (fr) 2005-06-01
CA2535760A1 (fr) 2004-02-26

Similar Documents

Publication Publication Date Title
NZ600690A (en) Fkbp-l and uses thereof
WO2006040357A3 (fr) Cibles et composes moleculaires et procedes d'identification afferents utiles dans le traitement de maladies de degenerescence des articulations et de maladies inflammatoires
JP2004504032A5 (fr)
WO2002080858A3 (fr) Utilisation de tripeptides kpv dans les etats dermatologiques
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
GB0404374D0 (en) Treatment of bacterial infections
Liu et al. Molecular characterization and functional analysis of the hepcidin gene from roughskin sculpin (Trachidermus fasciatus)
EP2114431A4 (fr) Composition contenant de l'arazyme destinée à la prévention et au traitement du cancer
WO2008047370A3 (fr) Compositions et méthodes permettant d'induire l'angiogenèse
CA2386231A1 (fr) Systeme de relargage de medicaments a base d'un peptide de translocation membranaire
WO2004016220A3 (fr) Voies d'apicomplexan, inhibiteurs et administration de medicaments
Qiu et al. Molecular cloning and mRNA expression of cyclophilin A gene in black tiger shrimp (Penaeus monodon)
CA2549185A1 (fr) Peptide inhibiteur de l'enzyme de conversion de l'angiotensine
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
WO2009044294A3 (fr) Moyens et procédés permettant le traitement de la cataracte et de la presbytie
WO2005107357A3 (fr) Composes analogues de peptides analgesiques derives du venin de serpents crotalus durissus terrificus, leurs applications, compositions et procedes destines a la preparation et a la purification de ces composes
WO2004074312A3 (fr) Peptides de tryptophylline et utilisations correspondantes
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
DE60304332D1 (de) Hydantoinracemase
WO2006078268A3 (fr) Peptide qui elicite les anticorps neutralisants ciblant le corecepteur vih, ccr5
WO2003097789A3 (fr) Nouveaux polypeptides purifies issus de pseudomonas aeruginosa
DE60325227D1 (fr)
WO2003060516A1 (fr) Methode de criblage
WO2004009633A8 (fr) Recepteur de serotonine
GB0228441D0 (en) Splice variant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003788516

Country of ref document: EP

Ref document number: 2003259848

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003788516

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2535760

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP